VMAC plus donor cells for AML relapse after transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests a combination treatment called VMAC (a chemotherapy) plus DLI (donor immune cells) for people whose AML has returned after a stem cell transplant. The goal is to see if this approach can help control the leukemia again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have AML (acute myeloid leukemia) that came back after a stem cell transplant.
- You are between 18 and 65 years old.
- You are well enough to be up and about (ECOG score 0-2).
- You have not had another cancer treatment in the past 3 years (except for some minor skin cancers).
- You do not have active heart disease, serious infections (like hepatitis B/C, HIV, or syphilis), or a mental condition that would make it hard to follow the study plan.
- If you are pregnant or could become pregnant, you must agree to use birth control during treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (mitoxantrone liposome plus others) for people with AML that has returned or hasn't responded to treatment. The goal is to see if the combination is safe and effective.
This trial tests a combination of three drugs (venetoclax, azacitidine, and liposomal mitoxantrone) as a first treatment for people newly diagnosed with acute myeloid leukemia (AML). The goal is to see if this combination works better than standard care.
This study tests a stronger pre-transplant conditioning regimen—using a liposome form of mitoxantrone with standard chemotherapy—to help wipe out remaining AML cells before a stem cell transplant. It is for people with higher-risk AML or who still have measurable disease before transplant.
This trial tests a new way to prevent graft-versus-host disease (a common side effect of stem cell transplant) using a drug called cyclophosphamide after transplant. It is for adults with certain blood cancers who need a transplant from a partially matched unrelated donor.
This trial tests a combination of three drugs (mitoxantrone liposome, cytarabine, and venetoclax) for people with AML that has returned or not responded to treatment. The goal is to see if this combination can help control the leukemia.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
Hear when a new Relapse Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.